Hippel James
Hippel James, CFO, reported a transaction classified as exercise at BIO-TECHNE Corp involving 9980.000000 shares for an estimated $0.00. Reported holdings after the transaction were 174694.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Aug 15, 2026
- Filing date
- Nov 02, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
Filing warnings
Notes recorded with this filingTECH price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0000914190-26-000171 Common Stock
- Transaction date
- Aug 15, 2026 Filed Nov 02, 2026, 09:40 PM · 79d delay
- Shares
- 9,980 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 174,694 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - amended_filing-6 points
is_amendment = true
Amended filing: the original transaction may have been restated. - delayed_filing-6 points
reporting_delay_days = 79
Filing delay exceeds the configured threshold.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
CFO
- F1
On 8/15/2026, the Board of Directors authorized discretionary vesting for 2,871 performance options. The remainder of the performance options were forfeited.
- F2
Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
- F3
On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,067 performance RSUs. The remainder of the performance RSUs were forfeited.
- F4
4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027.
- F5
4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
0 other transactions
0 recent txs